Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

Urologic Oncology: Seminars and Original Investigations - ResearchHub

ResearchHub

Research, connected

Explore the graph

X

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Help Article feed Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal

Urologic Oncology: Seminars and Original Investigations

1078-1439 · Elsevier BV

19 verified public works

Browse all journals →

The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer

2026 · 0 citations

Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric

2026 · 0 citations

Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen

2026 · 0 citations

Postoperative progression-free survival and clinicopathological risk stratification in urachal carcinoma: A multicenter retrospective cohort study

2026 · 0 citations

Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis

2026 · 0 citations

Editorial Board

2026 · 0 citations

FOCS-24: An integrated oncologic–functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer

2026 · 0 citations

Editorial comment: Is all gross hematuria high risk? Age-stratified outcomes after anticoagulation initiation using a large claims database

2026 · 0 citations

Editorial comment on clinical characteristics and oncological outcomes of upper tract urothelial carcinoma in patients with personal or family history of lynch-syndrome associated cancers

2026 · 0 citations

Comment on “Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice”

2026 · 0 citations

Cover 2 - Masthead

2026 · 0 citations

Response to editorial comment

2026 · 0 citations

Table of Contents

2026 · 0 citations

Editorial comment: FOCS-24: An integrated oncologic–functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer

2026 · 0 citations

Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care

2026 · 0 citations

Sociodemographic barriers to receiving adjuvant systemic therapy after nephrectomy for renal cell carcinoma

2026 · 0 citations

Re: Trans-perineal prostate biopsy—prognostic factors for “no prostate tissue” in biopsy cores: Beyond local anesthesia

2026 · 0 citations

Corrigendum to “Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition” Volume 35, Issue 10, October 2017, Pages 593-599

2026 · 0 citations

Featured SUO Fellow: Steven Monda, MD, MSCI

2026 · 0 citations

Page 1 of 1